Abstract 16P
Background
Granulosa cell tumors are uncommon ovarian cancers. Most patients have an early diagnosis, and they have a good prognosis generally. The only prognostic factor that has been proven to be positively correlated with survival is the stage at diagnosis. In this study, we sought to examine the clinical and pathological features of women treated at a single center after being diagnosed with malignant ovarian granulosa cell tumors.
Methods
Patients who had treatment or follow-up for the ten-year period (2012–2023) at Ege University Hospital after being diagnosed with an ovarian granulosa cell tumor were the subjects of a retrospective study. Information on the patient's age upon diagnosis, menopausal status, parity number, surgical procedure used, application complaint, tumor stage, recurrence status, disease-free survival (DFS), and overall survival (OS) was gathered. The location, size, mitotic index, inhibin A, and estrogen receptor level were among the pathological aspects of the tumor.
Results
A total of 56 patients were included in the study. 32% of the patients were between the ages of 46-55 at the time of diagnosis. Abdominal distension was the most common complaints, accounting for 37.5% of cases. A primary surgical staging procedure was performed in 92.8% of the patients. The tumor was 55% located in the left ovary. 71% of the patients were stage 1A at the time of diagnosis. Three patients had concurrent endometrial adenocarcinoma. 30.3% of the 17 patients had adjuvant therapy. With a rate of 41.1%, carboplatin+paclitaxel was the most often chosen regimen. It was shown that 9 individuals (16%) had recurrences. Three of these patients were in stage 3C, while six of them were in stage 1. Of the patients who experienced recurrence, 44.4% had peritoneal implants, 22.2% had visceral organ metastases, and 33.3% had local recurrence. Relapses occurred on average after 63 months. The patients' 5-year OS was 88.37%, and their 2-year OS was 98.18%.
Conclusions
These tumors have a decent prognosis but need to be followed up on for a long time. Survival and recurrence are mostly correlated with the tumor's early stages. Recurrence is also linked to the size of the tumor and the existence of residual tumor. To investigate how additional factors affect the result, more research is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.